Stereotaxis Inc (STXS) Stock Price, Quote & News

Company Profile

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as the Genesis RMN, which enable physicians to complete interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN, which is design...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 314 678 6100

Website: www.stereotaxis.com

Address:

710 North Tucker Boulevard, Suite 110, Saint Louis, United States

Georges8792 Oct. 8 at 5:30 AM

$STXS when will they install the first genesisX? Why does it take so long as

0 · Reply

TonySoprano1987 Oct. 7 at 12:31 PM

$STXS Could the shutdown cause delays at the FDA? So that approval might not come until early next year after all? What do you think? It wouldn't be a surprise. Delays are pretty much standard at that company :)

0 · Reply

S144 Oct. 7 at 8:38 AM

$STXS Key Pending FDA Approvals GenesisX Robotic System: This is the next-generation version of Stereotaxis' robotic magnetic navigation platform for electrophysiology procedures. It received CE Mark approval in Europe in 2024 and was submitted for FDA 510(k) clearance in August 2024. Clearance is expected later in 2025, supporting broader U.S. commercialization and upgrades from prior Genesis systems. MAGiC Ablation Catheter: A robotically navigated magnetic ablation catheter for treating cardiac arrhythmias. It was submitted for FDA clearance in early 2024 following positive clinical trial data. The company continues active dialogue with the FDA, with approval anticipated in fall 2025 (September-November). EMAGIN 5F Catheter: The first robotically navigated 5F guide catheter designed for broader endovascular applications beyond electrophysiology, such as neurointerventions. Submitted for FDA 510(k) clearance in March 2025, with approval expected in Q3 or Q4 2025.

0 · Reply

justbeermoney Oct. 6 at 9:10 PM

$STXS What’s everyone’s timeline on a roadmap to a 1Billion market cap or $200MILLION in revs , whichever comes first?

1 · Reply

AlJones Oct. 6 at 8:00 PM

$STXS : Held onto this for over a decade. Started around $8, then below $1, to pennies then now. 😱

0 · Reply

r3y Oct. 6 at 7:31 PM

$STXS adding..

0 · Reply

Eddypgil Oct. 6 at 6:58 PM

$STXS $4 soon

1 · Reply

inflect1on Oct. 6 at 6:50 PM

$STXS are u different this time? It has been a long while

0 · Reply

TonySoprano1987 Oct. 6 at 5:01 PM

$STXS break out when?

0 · Reply

zbenz Oct. 6 at 2:24 PM

$STXS where is Alex

1 · Reply

Erasmus Medical Center Advances Cardiovascular Care with Genesis Robotic System

Sep 2, 2025, 8:08 AM EDT - 5 weeks ago

First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter

Sep 2, 2025, 7:51 AM EDT - 5 weeks ago

Stereotaxis to Present at Upcoming Investor Conferences

Aug 28, 2025, 7:47 AM EDT - 5 weeks ago

Stereotaxis Technology to be Featured at Heart Rhythm Society's HRX 2025

Aug 8, 2025, 1:24 PM EDT - 2 months ago

Stereotaxis, Inc. (STXS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:01 PM EDT - 2 months ago

Stereotaxis Reports 2025 Second Quarter Financial Results

Jul 28, 2025, 7:48 AM EDT - 2 months ago

Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter

Jul 23, 2025, 8:00 AM EDT - 2 months ago

Stereotaxis to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 17, 2025, 8:32 AM EDT - 2 months ago

Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock

Jul 6, 2025, 2:13 AM EDT - 3 months ago

Stereotaxis: Recurring Revenue Inflection

Jul 1, 2025, 9:00 AM EDT - 3 months ago

First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology

May 12, 2025, 7:04 PM EDT - 5 months ago

Stereotaxis, Inc. (STXS) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 5 months ago

Stereotaxis Reports 2025 First Quarter Financial Results

Apr 22, 2025, 7:00 AM EDT - 6 months ago

Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025

Apr 21, 2025, 8:00 AM EDT - 6 months ago

Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025

Mar 19, 2025, 8:01 AM EDT - 7 months ago

Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA Connect Program

Mar 10, 2025, 8:02 AM EDT - 7 months ago

Stereotaxis to Present at 37th Annual Roth Conference

Mar 7, 2025, 9:10 AM EST - 7 months ago

Stereotaxis To Get FDA Approval Of MAGiC This Fall, Ending Cash Burn

Mar 3, 2025, 10:34 AM EST - 7 months ago

Stereotaxis, Inc. (STXS) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 7:32 AM EST - 7 months ago

Stereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery

Mar 3, 2025, 7:31 AM EST - 7 months ago

Stereotaxis Submits First Ever Robotically Navigated High-Density EP Mapping Catheter for Regulatory Clearance

Mar 3, 2025, 7:30 AM EST - 7 months ago

Stereotaxis Reports 2024 Full Year Financial Results

Feb 25, 2025, 8:03 AM EST - 8 months ago

Stereotaxis to Present at 45th Annual TD Cowen Healthcare Conference

Feb 14, 2025, 10:41 AM EST - 8 months ago

Stock Market Sleeps On Stereotaxis MAGiC CE Mark

Feb 3, 2025, 4:05 PM EST - 8 months ago

Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Jan 30, 2025, 8:09 AM EST - 8 months ago

Stereotaxis Announces First GenesisX Robotic System Order

Jan 27, 2025, 8:00 AM EST - 9 months ago

Stereotaxis Receives CE Mark Approval for the MAGiC Ablation Catheter

Jan 14, 2025, 7:21 AM EST - 9 months ago

Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology

Dec 9, 2024, 7:25 AM EST - 10 months ago

Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China's NMPA

Dec 2, 2024, 8:45 AM EST - 11 months ago

Stereotaxis' GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems

Dec 2, 2024, 5:03 AM EST - 11 months ago

Stereotaxis To Drive Transformational Growth Via Full Ecosystem Launch In 2025

Nov 26, 2024, 8:28 AM EST - 11 months ago

Stereotaxis to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 8:21 AM EST - 11 months ago

Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China

Nov 20, 2024, 8:18 AM EST - 11 months ago

Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System

Nov 11, 2024, 7:03 PM EST - 11 months ago

Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:02 PM EST - 11 months ago

Stereotaxis Reports 2024 Third Quarter Financial Results

Oct 21, 2024, 8:41 AM EDT - 1 year ago

Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation

Sep 3, 2024, 8:53 AM EDT - 1 year ago

Stereotaxis Robotic Technology to be Featured during Heart Rhythm Society's HRX Congress

Aug 25, 2024, 7:22 PM EDT - 1 year ago

Stereotaxis Receives CE Mark For GenesisX, Nears MAGiC Approval

Aug 12, 2024, 11:33 PM EDT - 1 year ago

Stereotaxis, Inc. (STXS) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Stereotaxis Reports 2024 Second Quarter Financial Results

Aug 12, 2024, 4:03 PM EDT - 1 year ago

Stereotaxis Achieves CE Mark in Europe and Submits 510(k) in the US for Next Generation Robotic System GenesisX

Jul 22, 2024, 4:05 PM EDT - 1 year ago

Stereotaxis to Report Second Quarter 2024 Financial Results on August 12, 2024

Jul 18, 2024, 4:13 PM EDT - 1 year ago

Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir

May 29, 2024, 8:25 AM EDT - 1 year ago

Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment

May 24, 2024, 8:37 AM EDT - 1 year ago

Stereotaxis Receives CE Mark Recertification Under EU's MDR Regulatory Framework

May 23, 2024, 4:38 AM EDT - 1 year ago

Stereotaxis Makes A Strategic Acquisition Bolstering Its Future

May 22, 2024, 8:42 AM EDT - 1 year ago

First Heart Rhythm Patients in Southern Italy Treated with Advanced Robotic Technology

May 15, 2024, 8:52 AM EDT - 1 year ago

Stereotaxis Invited by Africa Heart Rhythm Association to Present its Innovative Robotic Solution to Expand High-Quality Therapy in Underserved Regions of Africa

May 13, 2024, 7:52 PM EDT - 1 year ago

Stereotaxis, Inc. (STXS) Q1 2024 Earnings Call Transcript

Georges8792 Oct. 8 at 5:30 AM

$STXS when will they install the first genesisX? Why does it take so long as

0 · Reply

TonySoprano1987 Oct. 7 at 12:31 PM

0 · Reply

S144 Oct. 7 at 8:38 AM

0 · Reply

justbeermoney Oct. 6 at 9:10 PM

$STXS What’s everyone’s timeline on a roadmap to a 1Billion market cap or $200MILLION in revs , whichever comes first?

1 · Reply

AlJones Oct. 6 at 8:00 PM

$STXS : Held onto this for over a decade. Started around $8, then below $1, to pennies then now. 😱

0 · Reply

r3y Oct. 6 at 7:31 PM

$STXS adding..

0 · Reply

Eddypgil Oct. 6 at 6:58 PM

$STXS $4 soon

1 · Reply

inflect1on Oct. 6 at 6:50 PM

$STXS are u different this time? It has been a long while

0 · Reply

TonySoprano1987 Oct. 6 at 5:01 PM

$STXS break out when?

0 · Reply

zbenz Oct. 6 at 2:24 PM

$STXS where is Alex

1 · Reply

zbenz Oct. 6 at 2:21 PM

$STXS In the past , I've bought the 2.5 out-of - money calls out 3-4 months on a speculative basis on the eve of pending approvals like the CE mark , that dragged on for like 18 months , and got a goose egg on 5/5 ...now i'm buying the in the money 2.5 calls for a little extra exposure , in theory i wont get a zero if trend continues

0 · Reply

RemitTekram Oct. 6 at 1:34 PM

$STXS Very nice.

1 · Reply

_Not_Sure_ Oct. 5 at 7:07 PM

$STXS is anyone looking at call options? Five dollar strike price Feb and March? I’m confident that we’re gonna see share price go up. Maybe not so confident about any sort of timelineThoughts? though.

1 · Reply

zbenz Oct. 5 at 5:25 PM

$STXS agree, they can't afford to get too far out over their skis, stay focused and execute

0 · Reply

Playthegame06 Oct. 4 at 11:37 PM

$STXS STXS needs to keep a strong balance sheet and grow slowly. They can’t get over extended and be forced to sell at a cheap price. I like the CEO and he has a good plan!

0 · Reply

Playthegame06 Oct. 4 at 9:43 PM

$STXS STXS will not be sold for less than $5B. The only problem is they need to prove they are worth $5 Billion. It will take time and some FDA APPROVALS. I got screwed years ago on MAKO. Same situation (good robotics) and Stryker came in and bought them real cheap. If STXS continues to execute the MC will rise and radar signals will start flying around the big boys. Until then……keep buying.

1 · Reply

zbenz Oct. 4 at 1:42 PM

$STXS That would have to be one heck of a check book for any suitor, no way BOD would approve at this point in their development unless bid is super super sized

0 · Reply

semnyc Oct. 4 at 11:44 AM

$STXS I agree, get it now before it gets too expensive for them! Throw in MDT and ABT as others who could be interested!

0 · Reply

jpbailey37218 Oct. 3 at 11:44 PM

$STXS Intuitive Surgical needs to get their checkbook out… Times of wastin’!!

1 · Reply

alexpitti Oct. 3 at 11:23 PM

another 2 weeks in the books. i have an ear infection, but i should be healthy in 2-3 days huge data from $AUTL coming in october huge approvals for $STXS in October GenesisX & EMAGIN 5F & MAGiC Sweep ESMO in 2 weeks for $DCTH hopefully we can get the first procedure announced next week $ABEO kinda in no man's land right now

3 · Reply

Eddypgil Oct. 3 at 8:32 PM

$STXS buying now is wise. Pieces falling into place

0 · Reply

cheating_stock_investor Oct. 3 at 5:41 PM

$RR almost double and im done. $STXS is next.

0 · Reply

Market Cap	300.53M
Revenue (ttm)	26.92M
Net Income (ttm)	-24.05M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-89.34%
Debt to Equity Ratio	0.00

Volume	694,600
Avg Vol	498,586
Day's Range	N/A - N/A
Shares Out	91.07M
Stochastic %K	63%
Beta	1.65
Analysts	Strong Sell
Price Target	$4.33